Trilogy Stereotactic Body Radiotherapy for Pancreatic Cancer
Pancreatic Cancer
About this trial
This is an interventional treatment trial for Pancreatic Cancer focused on measuring Stereotactic Body Radiotherapy (SBRT), pancreas cancer, locally advanced, local control, Gemcitabine
Eligibility Criteria
Inclusion Criteria:- Pancreatic tumors not to exceed 10 cm in greatest axial dimension Histologically confirmed malignancies of the pancreas Unresectable by CT criteria or exploratory laparotomy or laparoscopy Patients with metastatic disease may be treated if they are symptomatic from the primary tumor Performance status of 0, 1, or 2 No chemotherapy two weeks prior or two weeks following radiosurgery Exclusion Criteria: patients who have had prior radiotherapy to upper abdomen patients receiving any prior pancreatic cancer therapy children, pregnant, and breastfeeding women, and lab personnel are excluded uncontrolled intercurrent illnesses any concurrent malignancy
Sites / Locations
- Stanford University School of Medicine
Arms of the Study
Arm 1
Experimental
Stereotactic Body Radiotherapy
Patients will have a 4D pancreatic protocol CT and a FDG PET scan scan, both for planning purposes. An SBRT treatment plan will be developed based on tumor geometry and location. All patients will receive a single fraction of 25 Gy dose of Stereotactic Body Radiotherapy on Trilogy Linear Accelerator, followed by weekly Gemcitabine.